Holen Sie sich die Stockscreener-App
13.67
1.23%
-0.17
Handel nachbörslich:
13.67
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
4D Molecular Therapeutics Insiders Sold US$757k Of Shares Suggesting Hesitancy - Simply Wall Street
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway - Seeking Alpha
4D Molecular Therapeutics Advances 4D-150 into Phase 3 for Diabetic Macular Edema with Initiation of 4Sight - marketscreener.com
4D Molecular Therapeutics Initiates Patient Enrollment in Phase 3 4SIGHT Trial for Diabetic Macular Edema - Kalkine Media
4D Molecular Therapeutics Begins Phase 3 4D-150 DME Trial - TipRanks
4D Molecular Therapeutics Begins Phase 3 Trial of 4D-150 in Diabetic Macular Edema - Yahoo Finance
A 9-person study reported 61% lower injection burden with 4D-150 versus a 13-shot projection. - Stock Titan
4D Molecular Therapeutics (FDMT) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock By Investing.com - Investing.com Nigeria
Live 4D Molecular Therapeutics, Inc. (FDMT) Technical Analysis - Traders Union
Form 4 4D Molecular Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria
Form 4 4D Molecular Therapeutics Inc For: 22 September - Investing.com India
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock - Investing.com India
4D Molecular (FDMT) legal chief exercises options, then sells 1,635 shares - Stock Titan
4D Molecular Therapeutics (Nasdaq:FDMT)Stock Analysis - Simply Wall Street
4D (FDMT) Stock Today: Rallies +5.45%, Resistance at $15.24 2026-09-17Volume Breakout Ideas - careplusvn.com
Insider David Kirn Sells 58,333 Shares of 4D Molecular Therapeutics Inc (FDMT) - GuruFocus
4D molecular therapeutics CEO Kirn sells $811,003 in stock - Investing.com
4D molecular therapeutics CEO Kirn sells $811,003 in stock By Investing.com - Investing.com UK
4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing - marketscreener.com
4D Molecular Therapeutics (FDMT) CEO sells 58K shares under preset plan - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
FDMT: 4D-150 gene therapy shows strong safety, efficacy, and commercial momentum in retinal diseases - TradingView
4D Molecular Therapeutics at Morgan Stanley conference: gene therapy push By Investing.com - Investing.com UK
Insider at 4D Molecular (NASDAQ: FDMT) plans new stock sale after recent trades - Stock Titan
4D Molecular Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
4D Molecular Therapeutics Grants RSUs to Seven New Non-Executive Employees - Quiver Quantitative
Seven new employees get 96,000 stock units from 4DMT - stocktitan.net
4DMT Announces New Employment Inducement Grants - GlobeNewswire
FDMT: Phase III data for 4D-150 in wet AMD and DME expected next year, targeting major treatment shifts - TradingView
FDMT: 4D-150 targets a paradigm shift in wet AMD with major phase III data expected next year - TradingView
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com Nigeria
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 - investing.com
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief trades 584 shares at $14 - Stock Titan
4DMT to Participate in Upcoming Investor Conferences - Yahoo Finance
4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7%Here's What Happened - MarketBeat
4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME - Bitget
4D (FDMT) Watch: Advances 13.86% to $16.76; Boundary Watch: Price Remains Between $15.92 Support and $17.60 Resistance in Latest TradingSMA Signal - vinanet.vn
David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale - Stock Titan
HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com
146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com Canada
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month HighTime to Buy? - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily Executes Stock Option Exercises and Sales Under 10b5-1 Plan - Kalkine Media
4D Molecular Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan
Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10%Time to Buy? - MarketBeat
Persistent Asset Partners Ltd Makes New $1.94 Million Investment in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com - Investing.com Nigeria
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - manilatimes.net
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
4D Molecular Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear - GuruFocus
4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results - MarketBeat
FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise - Stock Titan
4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss - Stock Titan
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):